1546-0096-11-S1-A186 1546-0096 Meeting abstract <p>OR10-002 - A novel TNFR1 transcript of TRAPS gene</p> RittoreC SanchezE SolerS AlbersM ObiciL McDermottMF TouitouI GrandemangeS

INSERM / CHU A.DE VILLENEUVE, Montpellier, France

University Medish Centrum, Utrecht, Netherlands

IRCCS Fundazion Policlinico San Matteo, Pavia, Italy

6.NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK

Pediatric Rheumatology <p>7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)</p>Meeting abstracts<p>7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)</p>Lausanne, Switzerland22-26 May 2013http://www.autoinflammation2013.com/appli/frmHome.aspx1546-0096 2013 11 Suppl 1 A186 http://www.ped-rheum.com/content/11/S1/A186 10.1186/1546-0096-11-S1-A186
8112013 2013Rittore et al; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Mutations in the TNFRSF1A gene encoding the TNF cell surface receptor, TNFR1, cause TNFR-associated periodic syndrome (TRAPS) and polymorphisms in TNFRSF1A, including rs4149570, rs767455 and rs1800692, are associated with inflammatory diseases.

Objectives

We describe a novel exon 2-spliced transcript, named TNFR1-d2, and the impact of these 3 SNPs on exon 2 splicing, transcriptional activity of TNFRSF1A and TRAPS phenotype.

Methods

Expression of TNFRSF1A transcripts was performed by RT-PCR in a range of human cells and tissues. Exon 2 splicing and transcriptional activity were analysed in HEK293T and SW480 cells by in vitro alternative splicing and luciferase assays, respectively. We constructed haplotypes containing rs4149570, rs767455 and rs1800692 in controls (n=70), TRAPS (n=111) and TRAPS-like patients (n=450) to compare their distribution and association with clinical features of TRAPS.

Results

TNFR1-d2 was expressed in a tissue-specific manner, whereas TNFR1 expression was ubiquitous. Alternative splicing assays revealed that the T-A-T haplotype at rs4149570-rs767455-rs1800692 showed the highest expression of exon 2-skipping product (p=0.02). Transcriptional activity from the T-T haplotype at rs4149570-rs1800692 was increased compared to the G-C haplotype (p=0.03). In TRAPS patients, rs1800692 T/T homozygotes were excessively rare (p<10-4) and TRAPS-like patients with this genotype experienced less fever.

Conclusion

Our study provides a novel mechanism of TNFRSF1A regulation whereby three polymorphisms in the promoter, exon 1 and intron 4 have a functional and combined effect on exon 2 splicing, via a coupling mechanism between transcription and splicing. These polymorphisms may impact the phenotype of TRAPS and TRAPS-like patients.

Competing interests

None declared.